English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

A targeting drug delivery system using folate-conjugated pluronic F127/chitosan core-shell nanoparticles was developed to deliver doxorubicin (DOX) to the target cancer cells. First, DOX was encapsulated in pluronic F127 micelle cores in the presence of sodium dodecyl sulfate (SDS) by a self-assembly method. To form a shell, a layer of either chitosan or folate-conjugated chitosan was deposited onto the pluronic micelles. The encapsulation efficiency was approximately 58.1±4.7%. The average size of the core-shell nanoparticles was 37.4±2.0 nm, while the zeta potential was 12.9±2.3 mV, indicating the presence of a shell layer and more stable particles. In an in vitro DOX release study, an initial burst release, followed by a sustained release, was observed within 24 hours. In addition, the core-shell nanoparticles showed greater cytotoxicity towards MCF-7 cells than free DOX, suggesting a better therapeutic efficacy in treating cancer.

Preparation of Folate-Conjugated Pluronic F127/Chitosan Core-Shell Nanoparticles Encapsulating Doxorubicin for Breast Cancer Treatment